4 years ago

Gyroscope Therapeutics Secures $148 Million Series C to Advance Gene Therapy for Eye Diseases

  • Gyroscope Therapeutics, a London-based clinical-stage gene therapy company, has raised $148 million in Series C funding

  • The round was led by Forbion, with participation from Sofinnova Investments, T

  • Rowe Price Associates, Tetragon Financial Group, an undisclosed healthcare focused fund, Fosun Pharma, Cambridge Innovation Capital and founding investor Syncona

  • The funds will be used to advance the clinical development of GT005, the company's lead investigational gene therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

  • GT005 has received Fast Track designation from the U.S

  • Food and Drug Administration and is being evaluated in Phase II clinical trials in two different genetically defined patient populations with GA.

      • ProblemHealthcare

      "treat diseases of the eye that cause vision loss and blindness"

      Solution

      "developing gene therapy beyond rare disease using proprietary OrbitTM subretinal delivery system for precise delivery to the back of the eye"

      Covered on